Search the GHTC website

Global health R&D delivers for Massachusetts

US government investment in global health R&D has delivered

Amount
$4.2 billion
to Massachusetts research institutions
Jobs
48,200+ new jobs
for Massachusetts
Massachusetts's top USG-funded global health R&D institutions

Massachusetts's top USG-funded global health R&D institutions

Moderna Therapeutics (including Valera)
$1.9 billion
Harvard T. H Chan School of Public Health (including School of Public Health AIDS Initiative*)
$281.9 million
Brigham and Women's Hospital
$227.2 million
Beth Israel Deaconess Medical Center
$226 million
Massachusetts General Hospital (including CAMTech and the General Hospital Corporation)
$225.2 million
University of Massachusetts Medical School (including MassBiologics)
$201.1 million
Children's Hospital Boston (including Children's Hospital Corporation)
$120.4 million
Boston University (including Medical Campus and Center for Global Health and Development)
$98.3 million
Broad Institute
$93.8 million
Harvard University
$91.7 million
Harvard Medical School
$91.4 million
Tufts University
$85.9 million
Dana-Farber Cancer Institute
$67.6 million
Boston Medical Center
$56.6 million
VentureWell
$53.6 million
Massachusetts Institute of Technology
$46.7 million
Thermo Fisher Scientific (including Life Technologies, Fisher Bioservices, and Mesa Biotech)
$40.2 million
Hologic Inc. (including Cytyc Prenatal Products Corp.)
$36.2 million
Microbiotix Inc.
$32 million
Brandeis University
$22.1 million
Northeastern University
$19.6 million
Aldatu Biosciences
$13.1 million
Immune Disease Institute Inc.*
$12.3 million
Public Health Vaccines LLC
$12.3 million
Lyndra Inc.
$10.5 million
IQuum Inc.*
$10.1 million
Tufts Medical Center
$9.3 million
University of Massachusetts Amherst
$9.1 million
Immunetics Inc.
$7.9 million
Whitehead Institute for Biomedical Research
$7.9 million
BlueWillow Biologics (formerly NanoBio Corporation)
$7.8 million
Charles River Laboratories (including Piedmont Research Center and BioFocus)
$7.6 million
The Forsyth Institute
$6.9 million
NovaBiotic Pharmaceuticals
$6.5 million
Harvard Pilgrim Health Care Inc.
$5.7 million
Fenway Health
$5.5 million
Kephera Diagnostics LLC
$5.3 million
Initiatives Inc.*
$4.4 million
Progenics Pharmaceuticals Inc.*
$4.3 million
Detectogen Inc.
$4.2 million
SeraCare Life Sciences
$4.1 million
Intelligent Bio-systems Inc.*
$3.8 million
Genocea Biosciences
$3.5 million
Worcester Polytechnic Institute
$3.5 million
Daktari Diagnostics Inc.*
$2.9 million
PhagePro Inc.
$2.9 million
Fraunhofer USA Inc.
$2.4 million
Elektrofi Inc.
$2.3 million
Ambergen Inc.
$2.1 million
The Home for Little Wanderers (including Boston Children's Services)
$2.1 million
Antagen Pharmaceuticals
$2 million
E25Bio*
$2 million
STC Biologics
$1.6 million
Diagnostic Vision Corp*
$1.2 million
Giner Inc.
$1.2 million
L.E.A.F. Pharmaceuticals (Formerly L.E.A.F Therapeutics)
$1.2 million
Spero Therapeutics Inc.
$1.2 million
TRITON Systems
$1.2 million
Boston College
$1 million
HydroGlyde Coatings LLC
$1 million
Sample6 Technologies Inc.*
$912 thousand
Boston Biomedical Research Institute*
$900 thousand
Quanterix
$853 thousand
Vaxess Technologies
$819 thousand
Innotech
$776 thousand
ProCrysta Biologic*
$688 thousand
Alnylam Pharmaceuticals
$629 thousand
MatTek Corporation
$549 thousand
University of Massachusetts Boston
$539 thousand
Versatope Therapeutics
$524 thousand
Clark University
$484 thousand
SeLux Diagnostics
$474 thousand
Howard M. Shapiro
$407 thousand
Physical Sciences Inc.
$380 thousand
Ancora Pharmaceuticals Inc.*
$364 thousand
Life Biosciences
$316 thousand
Tiba Biotech
$301 thousand
Venova Technologies
$300 thousand
Arteriocyte*
$286 thousand
Nexgen Arrays*
$277 thousand
Whalen Biomedical
$198 thousand
Genpass Technologies*
$167 thousand
Pulsar Clinical Technologies*
$163 thousand
Biosense Technologies Inc.
$136 thousand
Casterbridge Pharmaceuticals Inc.*
$130 thousand
Center for Integration of Medicine & Innovative Technology (CIMIT)
$79 thousand
CreaGen BioSciences
$9 thousand

Massachusetts's top areas of global health R&D by USG funding

45.4%
COVID-19
4.4%
Diarrheal diseases
17.6%
HIV/AIDS
4.2%
Malaria
4.4%
Neglected tropical diseases
Dengue
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Leprosy
Mycetoma
14%
Tuberculosis
3.7%
Zika
6.3%
Other
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Chikungunya
Cryptococcal meningitis
Emergent non-polio enteroviruses (including EV71, D68)
Filoviral diseases (including Ebola, Marburg)
Hepatitis B
Hepatitis C
Histoplasmosis
Mpox
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Reproductive health
Salmonella infections
Global health R&D at work in Massachusetts

A research consortium involving scientists from Partners in Health and Harvard Medical School led a pair of clinical trials that could revolutionize the treatment of multidrug-resistant tuberculosis (MDR-TB). These first-of-their-kind trials in the tuberculosis (TB) space simultaneously evaluated five new treatment regimens, involving a combination of two newly approved TB drugs—bedaquiline and delamanid—alongside drugs used for other diseases. Conventional treatments for MDR-TB can take up to two years and involve thousands of pills and painful injections with serious side effects. While research remains ongoing, the goal of the trials is to advance shorter, less toxic, and all-oral regimens to treat the growing threat of MDR-TB.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Ruhani Kaur